Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000692 · ClinicalTrials.gov registry record · Phase 1
Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex
A Phase 1 study, sponsored by G D Searle.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00000692: Completed Phase 1 study, sponsored by G D Searle.
NCT00000692 is a Phase 1 study that has completed, run by G D Searle. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000692, a Phase 1 study, has completed, sponsored by G D Searle.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how long it remains in the patient's blood. SC-48334 is a chemical that prevents the biochemical actions of certain enzymes in the body, and recent studies have shown that it may also prevent the activity of HIV. The study will attempt to show whether SC-48334 can safely and effectively break the cycle of HIV infection in AIDS and advanced ARC by progressively eliminating HIV.
Interventions
- DRUG Butyldeoxynojirimycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000692
The ClinicalTrials.gov registry entry for NCT00000692 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is G D Searle, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Butyldeoxynojirimycin is the first listed.
NCT00000692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000692 about?
NCT00000692 is a clinical study titled "Phase I Rising Dose Tolerability Study of SC-48334 in Patients With Acquired Immunodeficiency Syndrome (AIDS) and Advanced AIDS Related Complex". To determine the following about the use of SC-48334 in patients with AIDS and advanced AIDS related complex (ARC): 1\. The largest maximum tolerated dose (MTD); 2. Effectiveness against HIV; 3. Pharmacokinetics - how fast SC-48334 reaches the bloodstream, what concentration is reached, and how lon...
What is the current status of trial NCT00000692?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants.
What interventions are being tested in trial NCT00000692?
The interventions under investigation include: Butyldeoxynojirimycin (DRUG).
Who is sponsoring clinical trial NCT00000692?
This trial is sponsored by G D Searle, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.